Pharmacologic treatment of atherosclerosis: Beyond lipid-lowering theraphy

International Journal of Cardiology

Volumn 62, Issue SUPPL. 2, 1997, Pages

  Marche, Pierre ^a   Hérembert, Thierry ^a   Zhu, Ding Liang ^b  

^a CNRS   (France)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Calcium antagonists; Smooth muscle cells

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIHYDROPYRIDINE DERIVATIVE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; NITRENDIPINE; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; GROWTH REGULATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CELLS, CULTURED; HUMANS; LIPIDS; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 0344352506     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00237-4     Document Type: Conference Paper

References (44)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
2. Habenicht A.J.R., Glomset J.A., Ross R. Relation of cholesterol and mevalonic acid to the cell cycle in smooth muscle cell and Swiss 3T3 cells stimulated to divide by platelet derived growth factor. J Biol Chem. 255:1980;5134-5140.
3. Jakobisiak M., Bruno S., Skierski J., Darzynkiwicz Z. Cell-specific effects of lovastatin. Proc Natl Acad Sci USA. 88:1991;3628-3632.
4. McGuire T.F., Corey S.J., Sebti S.M. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylatyed PDGF receptor. J Biol Chem. 268:1993;22227-22230.
5. Hidaka Y., Eda T., Yonemoto M., Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis. 95:1992;87-94.
6. Bondjers G., Glukhova M., Hansson G., Postnov Y.V., Reidy M.A., Schwartz S.M. Hypertension and atherosclerosis. Cause and effect, or two effects with one unknown cause? Circulation. 84(Suppl VI):1991;VI2-VI16.
7. Omoigui N., Dzau V.J. Differential effects of antihypertensive agents in experimental and human atherosclerosis. Am J Hypertens. 6:1993;30S-39S.
8. Mulvany M.J., Hansen P.K., Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media and an increased number of smooth muscle cell layers. Circ Res. 43:1978;854-864.
9. Owens G.K., Schwartz S.M. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat. Circ Res. 51:1982;280-289.
10. Marche P., Hérembert T., Zhu D.L. Molecular mechanisms of vascular hypertrophy in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol. 22(Suppl 1):1995;S114-S116.
11. Yamori Y., Igawa T., Kanbe T., Kihara M., Nara Y., Horie R. Mechanisms of structural vascular changes in genetic hypertension: analyses on cultured vascular smooth muscle cells from spontaneously hypertensive rats. Clin Sci. 61:1981;121s-123s.
12. + exchange. J Clin Invest. 83:1989;822-829.
13. Hadrava V., Tremblay J., Hamet P. Abnormalities in growth characteristics of aortic smooth muscle cells in spontaneously hypertensive rats. Hypertension. 13:1989;589-597.
14. Zhu D.L., Hérembert T., Marche P. Increased proliferation of adventitial fibroblasts from spontaneously hypertensive rat aorta. J Hypertens. 9:1991;1161-1168.
15. cdc2 in cultured aortic adventitial fibroblasts derived from spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens. 11:1993;483-489.
16. Bolzon B.J., Cheung D.W. Isolation and characterization of single vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 14:1989;137-144.
17. Resink T.J., Scott-Burden T., Baur U., Burgin M., Bühler F.R. Enhanced responsiveness to angiotensin II in vascular smooth muscle cells from spontaneously hypertensive rats is not associated with alterations in protein kinase C. Hypertension. 14:1989;293-303.
18. Ishimitsu T., Uehara Y., Ishii M., Ikeda T., Matsuoka H., Sugimoto T. Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats. Hypertension. 12:1988;46-51.
19. Sugiyama T., Yoshizumi M., Takaku F., Yazaki Y. Abnormal calcium handling in vascular smooth muscle cells of spontaneously hypertensive rats. J Hypertens. 8:1990;369-375.
20. Orlov S., Resink T.J., Bernhardt J., Ferracin F., Böhler F.R. Vascular smooth cell calcium fluxes. Regulation by angiotensin II and lipoproteins. Hypertension. 21:1993;195-203.
21. Yagisawa H., Tanase H., Nojima H. Phospholipase C-δ gene of the spontaneously hypertensive rat harbors point mutations causing amino acid substitutions in a catalytic domain. J Hypertens. 9:1991;997-1004.
22. Zhu D.L., Hérembert T., Marche P. Mitogenic events induced by vasopressin in aortic fibroblasts from spontaneously hypertensive rats. Clin Sci. 85:1993;57-61.
23. Zhu D.L., Hérembert T., Marche P. Protein kinase C and cell proliferation in spontaneously hypertensive rats. Clin Exp Hypertens. 14:1992;875-887.
24. Zhu D.L., Hérembert T., Caruelle D., Caruelle J.P., Marche P. Signaling mechanisms of basic fibroblast growth factor in arterial cells from genetically hypertensive rat. Am J Hypertens. 7:1994;351-356.
25. 1 gene activation and growth of smooth muscle from hypertensive rats. Hypertension. 23:1994;593-599.
26. Kondo T., Inui H., Konishi F., Inagami T. Enhanced phospholipase D activity in vascular smooth muscle cells derived from spontaneously hypertensive rats. Clin Exp Hypertens. 16:1994;17-28.
27. Nayler WG. The voltage-activated, calcium antagonist-sensitive calcium channels: their structure, composition and calcium antagonist binding sites. In: Nayler WG, editor. Amlodipine. Berlin, New York: Springer-Verlag, 1993:23-35.
28. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension. 20:1992;713-736.
29. 2+-channel blockers modulate expression of 3-HMG CoA reductase and LDL receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci USA. 88:1991;9041-9045.
30. Zhu D.L., Hérembert T., Caruelle D., Caruelle J.P., Marche P. Involvement of calcium channels in fibroblast growth factor-induced activation of arterial cells in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 23:1994;395-400.
31. Hermsmeyer K., White A.C., Triggle D.J. Decreased dihydropyridine receptor number in hypertensive rat vascular smooth muscle cells. Hypertension. 25:1995;731-734.
32. Uehara Y., Kawabata Y., Hirawa N., Takada S., Numabe A., Matsuoka H., Ikeda T., Takabatake Y., Yagi S., Sugimoto T. OPC-13340, a new dihydropyridine calcium-channel blocker attenuates rapid vascular smooth muscle cell growth in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 20:1992;408-415.
33. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., Tamai T., Nakai T., Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20:1992;900-906.
34. Cornwell T.L., Arnold E., Boerth N.J., Lincoln T.M. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol. 267:1994;C1405-413.
35. Nayler WG. Calcium antagonists. In: Nayler WG, editor. Calcium antagonists. London: Academic Press, 1988:157-260.
36. McMurray H.F., Chahwala S.B. Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20(Suppl A):1992;S54-S56.
37. Holzgreve H., Bürkle B. Anti-atherosclerotic effects of calcium antagonists. J Hypertens. 11(Suppl 1):1993;S55-S59.
38. Nayler WG. The anti-atherogenic potential of the calcium antagonists, including amlodipine. In: Nayler WG, editor. Amlodipine. Berlin, New York: Springer-Verlag, 1993:178-198.
39. Nayler WG. Amlodipine. A long-acting second generation calcium antagonist with an unusual binding profile. In: Nayler WG, editor. Amlodipine. Berlin, New York: Springer-Verlag, 1993:45-60.
40. Nayler WG. The vascular selectivity of amlodipine. In: Nayler WG, editor. Amlodipine. Berlin, New York: Springer-Verlag, 1993:73-88.
41. Nayler WG. Calcium antagonists and the treatment of hypertension. In: Nayler WG, editor. Amlodipine. Berlin, New York: Springer-Verlag, 1993:148-177.
42. Tulenko T.N., Stepp D.W., Chen M., Moisey D., Laury-Kleintop L., Mason R.P. Actions of the charged dihydropyridine, amlodipine, in a cell culture model of dietary atherosclerosis. J Cardiovasc Pharmacol. 26(Suppl A):1995;S11-S17.
43. Orekhov A.N., Tertov V.V., Pivovarova E.M. The effects of anti-hypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. J Cardiovasc Pharmacol. 26(Suppl A):1995;S25-S33.
44. Catt K.J., Hunyady L., Balla T. Second messengers derived from inositol lipids. J Bioenerg Biomembr. 23:1991;7-27.